However, up to 30% of ER+ breast cancer patients are initially resistant to tamoxifen, and approximately 40% of patients with ER+ breast cancer that initially responded to tamoxifen eventually develop resistance [51]. This evidence concerns the gene ESR1 and breast carcinoma.